Logotipo del repositorio

Manifestaciones clínicas Posagudas y calidad de vida de pacientes atendidos por Covid-19 en una institución de la red pública de Barranquilla, de enero a julio del 2021

Vista sencilla de ítem
dc.contributor.advisorZuluaga De León, Iván
dc.contributor.advisorNavarro Baene, Gina
dc.contributor.authorCastellón De La Rosa, Evis Adriana
dc.contributor.authorJiménez Arcia, Luisa Fernanda
dc.coverage.spatialBarranquillaspa
dc.creator.emailevis.adriana.castellon@gmai.comspa
dc.creator.emailluisajimenezmd@gmail.comspa
dc.date.accessioned2022-12-05T20:27:53Z
dc.date.available2022-12-05T20:27:53Z
dc.date.created2022
dc.description.abstractOBJETIVO GENERAL Determinar las manifestaciones clínicas posagudas y nivel de calidad de vida a 6 meses en pacientes atendidos por COVID-19 en el Hospital General de Barranquilla, durante el periodo de enero a julio de 2021. METODOLOGÍA Estudio descriptivo, longitudinal, prospectivo. Los datos fueron obtenidos del Hospital General de Barranquilla y el seguimiento a 6 meses se realiza— por vía telefónica mediante encuesta de síntomas y escala SF12. El análisis se hizo mediante el programa SPSS en su versión 15. Se emplearon medidas descriptivas para el análisis univariado: porcentaje y promedio y desviación estándar. Para el análisis bivariado se emplea— prueba t.Ê RESULTADOS De 16 manifestaciones clínicas postagudas descritas en la literatura, la disnea y la fatiga, fueron las más frecuentes, con 42,2% y 41,3%, respectivamente, el resto de las manifestaciones estuvieron entre 13,9% y 28,3%. El resultado de los componentes de salud física y salud mental, según el SF-12, muestran que, en ninguno de los casos el promedio llega a 50 puntos, siendo más bajo para salud física (Prom: 38,1 +/-5,5). ??Al comparar los promedios de salud física y emocional según las variables sociodemográficas, se encontraron diferencias significativas (p<0,05) para el sexo (mayor puntaje en hombres) en salud física y para el estrato (mayor puntaje en el estrato dos) en salud mental. Al relacionar los promedios de las dimensiones salud física y salud mental según cada una de las manifestaciones clínicas postagudas, no se encontraron diferencias significativas en ninguno de los casos, con excepción—n del dolor torácico en la primera dimensión. CONCLUSIONES La dificultad respiratoria y la fatiga fueron las manifestaciones más frecuentes. Los puntajes del SF-12 tanto para el componente de salud física como para el de salud mental fueron relativamente bajos en la mayoría de los participantes, por lo que solamente se encontraron diferencias significativas al cruzar salud física con sexo y salud mental con estrato socioeconómico, para el caso de las variables sociodemográficas. Para las manifestaciones clínicas postagudas no hubo diferencias significativas entre los que las padecían y los que no.spa
dc.description.abstractenglishGENERAL OBJECTIVE To determine the post-acute clinical manifestations and level of quality of life at 6 months in patients treated for COVID-19 at the General Hospital of Barranquilla, during the period from January to July 2021. METHODOLOGY Descriptive, longitudinal, prospective study. The data were obtained from the General Hospital of Barranquilla and the 6-month follow-up was carried out by telephone using a symptom survey and the SF12 scale. The analysis was done using the SPSS program in its version 15. Descriptive measures were used for the univariate analysis: percentage and mean and standard deviation. For the bivariate analysis, a t-test was used. RESULTS Of 16 post-acute clinical manifestations described in the literature, dyspnea and fatigue were the most frequent, with 42.2% and 41.3%, respectively, the rest of the manifestations appeared between 13.9% and 28.3%. The result of the physical health and mental health components, according to the SF-12, shows that, in none of the cases, the average reached 50 points, being lower for physical health (Average: 38.1 +/-5,5). When comparing the averages of physical and emotional health according to the sociodemographic variables, significant differences (p<0.05) were found for gender (higher score in men) in physical health and for the stratum (higher score in stratum two) in mental health. When relating the averages of the physical health and mental health dimensions according to each of the post-acute clinical manifestations, no significant differences were found in any of the cases, except for chest pain in the first dimension. CONCLUSIONS Respiratory distress and fatigue were the most frequent manifestations. The SF-12 scores for both the physical health and mental health components were relatively low in most of the participants, so significant differences were only found when crossing physical health with gender and mental health with socioeconomic status. for the case of sociodemographic variables. For post-acute clinical manifestations, there were no significant differences between those who suffered from them and those who did not.spa
dc.description.sponsorshipUniversidad Libre Seccional Barranquilla -- Facultad de Ciencias de la Salud -- Especialización en Medicina Internaspa
dc.formatPDFspa
dc.identifier.urihttps://hdl.handle.net/10901/23839
dc.relation.referencesWho.int (Internet). Estados Unidos: Whoint; 2000 [actualizado 06 de noviembre 2020; citado 1 de noviembre de 2020. Tomado de: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public Fecha de acceso: febrero de 2021spa
dc.relation.referencesCoronavirus.jhu.edu. Estados Unidos: coronavirus.jhu.edu; 2020. Tomado de: https://coronavirus.jhu.edu/map.html Fecha de acceso: febrero de 2021spa
dc.relation.referencesGreenhalgh T, Knight M, A’Court C, Buxton M, Husain L. Management of postacute COVID-19 in primary care. BMJ. 2020;370:m3026spa
dc.relation.referencesDel Rio C, Collins L, Malani P. Long-term health consequences of COVID19. Jama, 2020; 324(17): 1723-1724spa
dc.relation.referencesHuang Y, Tan C, Wu J, Chen M, Wang Z, Luo L, Zhou X et al. Impact of Coronavirus disease 2019 on pulmonary function in early convalescence phase. Respir Res. 2020; 21:163spa
dc.relation.referencesCarfi A, Bernabei R, Landi F. Persistent Symptoms in Patients After Acute COVID -19. JAMA. 2020; 324(6):603-605spa
dc.relation.referencesBao Y, Sun Y, Meng S, Shi J, Lu L. 2019-nCoV epidemic: address mental health care to empower society. The Lancet, 2020; 395(10224): e37-e38spa
dc.relation.referencesXu Z, Li S, Tian S, Li H, Kong L. Full spectrum of COVID-19 severity still being depicted. Lancet, 2020; 395(10228): 947spa
dc.relation.referencesJack A. Why the panic? South Korea’s MERS response questioned. Bmj, 2015; 350(1): h3403spa
dc.relation.referencesAbdel-Moneim A. Middle East respiratory syndrome coronavirus: Is it worth a world panic? World journal of virology, 2015; 4(3): 185-187spa
dc.relation.referencesBrooks S, Webster R, Smith L, Woodland L, Wessely S, Greenberg N, Rubin G. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. The Lancet, 2020; 395(10227): P912-P920spa
dc.relation.referencesArab-Zozani M, Hashemi F, Safari H, Yousefi M, Ameri H. Health-Related Quality of Life and its Associated Factors in. COVID-19 Patients. Osong Public Health Res Perspect 2020;11(5):296-302spa
dc.relation.referencesPiedra J, Cuellar C, Machado V. Instrumentos evaluadores de secuelas en pacientes postinfección a COVID-19. Su utilidad en rehabilitación. Revista Cubana de Medicina Física y Rehabilitación, 2020; 12(3): 1-22spa
dc.relation.referencesValdés M. Las enfermedades crónicas no transmisibles y la pandemia por COVID-19. Revista Finlay, 2020; 10(2): 78-88spa
dc.relation.referencesMaley J, Brewster I, Mayoral I, Siruckova R, Adams S, McGraw K, Mikkelsen M. Resilience in survivors of critical illness in the context of the survivors’ experience and recovery. Ann Am Thorac Soc. 2016;13(8):1351-1360spa
dc.relation.referencesCarfì A, Bernabei R, Landi F. Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA, 2020;324(6):603-605spa
dc.relation.referencesTenforde M, Kim S, Lindsell C y cols.; IVY Network Investigators; CDC COVID19 Response Team; IVY Network Investigators. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network: United States, March-June 2020. MMWR Morb Mortal Wkly Rep. 2020;69(30):993-998spa
dc.relation.referencesCaliari D, Campos K, Dos Santos P, Louro S, Curty T, Mendanha T, Dos Reis E. Associação entre las características sociodemográficas y síntomas da COVID-19 em pacientes residentes do Espírito Santo, Brasil: Association between the sociodemographic characteristics and COVID-19 symptoms in patients resident in Espírito Santo state, Brazil. Health and Biosciences, 2020; 1(2): 32-51spa
dc.relation.referencesInstituto Nacional de Salud. Coronavirus. Tomado de: https://www.ins.gov.co/Noticias/Paginas/Coronavirus.aspx Fecha de acceso: febrero de 2021spa
dc.relation.referencesRothan H, Byrareddy S. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of autoimmunity, 2020; 109(1): 102433spa
dc.relation.referencesPuntmann V, Carerj M, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol. Published online July 27, 2020. doi:10.1001/jamacardio.2020.3557spa
dc.relation.referencesRajpal S, Tong M, Borchers J, Zareba K, Obarski T, Simonetti O, Daniels C. Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection. JAMA cardiology, 2021; 6(1): 116-118spa
dc.relation.referencesZhao Y, Shang Y, Song W, Li Q, Xie H, Xu Q, Luo H. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine, 2020; 25(1): 100463spa
dc.relation.referencesZubair A, McAlpine L, Gardin T, Farhadian S, Kuruvilla D, Spudich S. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol. 2020;77(8):1018-1027spa
dc.relation.referencesGalea S, Merchant R, Lurie N. The mental health consequences of COVID19 and physical distancing: the need for prevention and early intervention. JAMA Intern Med. 2020;180(6):817-818spa
dc.relation.referencesWare J, Kosinski M, Keller S. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Medical care, 1996; 34(1): 220-233spa
dc.relation.referencesCleaton N, Raizada S, Barkham N, Venkatachalam S, Sheeran T, Adizie T, Bateman J. COVID-19 prevalence and the impact on quality of life from stringent social distancing in a single large UK rheumatology centre. Annals of the Rheumatic Diseases, 2021; 80(6): e93-e93spa
dc.relation.referencesLiu C, Stevens C, Conrad R, Hahm H. Evidence for elevated psychiatric distress, poor sleep, and quality of life concerns during the COVID-19 pandemic among US young adults with suspected and reported psychiatric diagnoses. Psychiatry research, 2020; 292(1): 113345spa
dc.relation.referencesDi Stefano V, Battaglia G, Giustino V, Gagliardo A, D’Aleo M, Giannini O, Brighina F. Significant reduction of physical activity in patients with neuromuscular disease during COVID-19 pandemic: the long-term consequences of quarantine. Journal of neurology, 2020; 1(1): 1-7spa
dc.relation.referencesWalline J. COVID -19- Quality of Life After Infection. Clinical Trials. gov: NCT04377464. Chinese University of Hong Kong. 2020. disponible en https://clinicaltrials.gov/ct2/show/NCT04377464#contactsspa
dc.relation.referencesSaavedra C, Buitrago A, Jiménez A, Mejía A, Narváez A, Rojas A, et al. Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVID-19 en establecimientos de atención de la salud. Infectio. 2020; 24 (3):1-153spa
dc.relation.referencesMaréchal M, Morand P, Epaulard O, Némoz B. COVID-19 in clinical practice: a narrative synthesis. Med Mal Infect, 2020; 50(20): 30710-1spa
dc.relation.referencesGordon D, Jang G, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARSCoV-2 protein interaction map reveals targets for drug repurposing. Nature 2020; 583spa
dc.relation.referencesHou YJ, Okuda K, Edwards CE, Martinez DR, Asakura T, Dinnon KH, et al. SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. Cell. 2020;2spa
dc.relation.referencesHoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181:271-280.e8spa
dc.relation.referencesChan J, Yuan S, Kok K, Wang K, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-toperson transmission: a study of a family cluster. Lancet. 2020; 395: 514–23spa
dc.relation.referencesLei J, Li J, Li X, Qi X. CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology, 2020; 295(1): 18-18spa
dc.relation.referencesLu H. Drug treatment options for the 2019-new coronavirus (2019- nCoV). Bioscience trends, 2020;14(1): 69-71spa
dc.relation.referencesHuang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Cheng Z. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet, 2020; 395(10223): 497-506spa
dc.relation.referencesLuo W, Yu H, Gou J, Li X, Sun Y, Li J, Liu L. Clinical pathology of critical patient with novel coronavirus pneumonia (COVID-19). Preprints, 2020: 2020020407spa
dc.relation.referencesBonaventura A, Vecchié A, Dagna L, Martinod K, Dixon D, Van Tassell B, Abbate A. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nature Reviews Immunology, 2021; 21(5): 319- 329spa
dc.relation.referencesLi Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Xing X. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. New England Journal of Medicine, 2020; 382(1):1199-1207spa
dc.relation.referencesWang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol, 2020; 92(4): 441– 447spa
dc.relation.referencesCarlos W, Dela Cruz C, Cao B, Pasnick S, Jamil S. Novel wuhan (2019-nCoV) coronavirus. Am J Respir Crit Care Med, 2020; 201(4): 7–8spa
dc.relation.referencesAssiri A, Al-Tawfiq J, Al-Rabeeah A, Al-Rabiah F, Al-Hajjar S, Al-Barrak A, Makhdoom H. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. The Lancet infectious diseases, 2013; 13(9): 752- 761spa
dc.relation.referencesPhan L, Nguyen T, Luong Q, Nguyen T, Nguyen H, Le H, Pham Q. Importation, and human-to-human transmission of a novel coronavirus in Vietnam. New England Journal of Medicine, 2020; 382(9), 872-874spa
dc.relation.referencesLi X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, Zhang C. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. Journal of Allergy and Clinical Immunology, 2020; 146(1): 110-118spa
dc.relation.referencesGuan W, Ni Z, Hu Y, Liang W, Ou C, He J, Du B. Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine, 2020; 382(18): 1708-1720spa
dc.relation.referencesHe L, Ding Y, Zhang Q, Che X, He Y, Shen H, Deng Y. Expression of elevated levels of pro‐inflammatory cytokines in SARS‐CoV‐infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland, 2006; 210(3): 288-297spa
dc.relation.referencesSheng W, Chiang B, Chang S, Ho H, Wang J, Chen Y, Yang P. Clinical manifestations, and inflammatory cytokine responses in patients with severe acute respiratory syndrome. Journal of the Formosan Medical Association= Taiwan yi zhi, 2005; 104(10): 715-723spa
dc.relation.referencesZhang J, Dong X, Cao Y, Yuan Y, Yang Y, Yan Y, Gao Y. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy, 2020; 75(7): 1730-1741spa
dc.relation.referencesWu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, Song J. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA internal medicine, 2020; 180(7): 934-943spa
dc.relation.referencesCrackower M, Sarao R, Oudit G, Yagil C, Kozieradzki I, Scanga S, Scholey J. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature, 2002; 417(6891): 822-828spa
dc.relation.referencesLineamientos para el uso de pruebas diagnósticas para SARS-CoV-2 (COVID-19) en Colombia. Ministerio de salud y protección social. Marzo 2022spa
dc.relation.referencesCorman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020 Jan 1;25(3)spa
dc.relation.referencesU.S. Department of Health & Human Services (2020) Real-Time RT-PCR Panel for Detection 2019-Novel Coronavirus. 24 Jan 2020. En: https://www.cdc.gov/coronavirus/2019-ncov/downloads/rt-pcr-panel-fordetectioninstructions.pdf. 2014spa
dc.relation.referencesLiu R, Han H, Liu F, Lv Z, Wu K, Liu Y, Zhu C. Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020. Clinica Chimica Acta, 2020; 505(1): 172-175spa
dc.relation.referencesAi T, Yang Z, Hou H, Zhan C, Chen C, Lv W, Xia L. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology, 2020; 200642spa
dc.relation.referencesThoracic S. Expert consensus for bronchoscopy during the epidemic of 2019 novel coronavirus infection (Trial version). Zhonghua jie he hu xi za zhi= Zhonghua jiehe he huxi zazhi= Chinese journal of tuberculosis and respiratory diseases, 2020;43(3): 199spa
dc.relation.referencesTrujillo C. Resumen: Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVID-19 en establecimientos de atención de la salud. Infectio, 2020; 24(3): 1- 175spa
dc.relation.referencesVillarroel P, Silva J, Atenas C, Pavez P. Evaluación del cuestionario SF-12: verificación de la utilidad de la escala salud mental. Rev Med Chile 2014; 142: 1275-1283spa
dc.relation.referencesUrzúa A, Caqueo-Urízar A. Calidad de vida: Una revisión teórica del concepto. Ter Psicol 2012; 30 (1): 61-72spa
dc.relation.referencesRebollo P. Utilización del «grupo SF» de los cuestionarios de calidad de vida (SF-36, SF-12 y SF-6D) en el marco de ensayos clínicos y en la práctica clínica habitual. Med Clin (Barc) 2008; 130 (19): 740-1spa
dc.relation.referencesWölfel R, Corman V, Guggemos W, Seilmaier M, Zange S, Müller M, Hoelscher M. Virological assessment of hospitalized patients with COVID2019. Nature, 2020; 581(7809): 465-469spa
dc.relation.referencesZhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, Qian S. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clinical Infectious Diseases, 2020; 71(16): 2027-2034spa
dc.relation.referencesTo K, Tsang O, Leung W, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20(5):565-574spa
dc.relation.referencesWu L, Wang N, Chang Y, et al. Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2007;13(10):1562-1564spa
dc.relation.referencesPayne D, Iblan I, Rha B, et al. Persistence of antibodies against Middle East respiratory syndrome coronavirus. Emerg Infect Dis. 2016;22(10):1824-1826spa
dc.relation.referencesXing Y, Mo P, Xiao Y, Zhao O, Zhang Y, Wang F. Post-discharge surveillance and positive virus detection in two medical staff recovered from coronavirus disease 2019 (COVID-19), China, January to February 2020. euro Surveill. 2020;25(10). doi:10.2807/1560-7917.ES.2020.25.10.2000191spa
dc.relation.referencesXiao A, Tong Y, Zhang S. False‐negative of RT‐PCR, and prolonged nucleic acid conversion in COVID‐19: rather than recurrence. Journal of medical virology, 2020; 92(10): 1755-1766spa
dc.relation.referencesYoung BE, Ong S, Kalimuddin S, et al; Singapore 2019 Novel Coronavirus Outbreak Research Team. Epidemiologic features and clinical course of patients with SARS-CoV-2 in Singapore. JAMA. 2020;232(15):1488-1494spa
dc.relation.referencesKirkcaldy R, King B, Brooks J. COVID-19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions. Jama, 2020; 323(22): 2245-2246spa
dc.relation.referencesXiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, Dong W. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clinical Microbiology and Infection, 2020; 27(1): 89-95spa
dc.relation.referencesNalbandian A, Sehgal K, Gupta A, Madhavan M, McGroder C, Stevens J, Wan y cols. Post-acute COVID-19 syndrome. Nature medicine, 2021; 1-15spa
dc.relation.referencesLogue J, Franko N, McCulloch D, McDonald D, Magedson A, Wolf C, Chu H. Sequelae in adults at 6 months after COVID-19 infection. JAMA network open, 2021; 4(2): e210830-e210830spa
dc.relation.referencesHalpin S, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, Sivan M. Postdischarge symptoms and rehabilitation needs in survivors of COVID‐19 infection: A cross‐sectional evaluation. Journal of medical virology, 2021; 93(2): 1013-1022spa
dc.relation.referencesGarrigues E, Janvier P, Kherabi Y, Le Bot A, Hamon A, Gouze H, Nguyen Y. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. Journal of Infection, 2020; 81(6): e4-e6spa
dc.relation.referencesChopra V, Flanders S, O'Malley M, Malani A, Prescott H. Sixty-Day Outcomes Among Patients Hospitalized With COVID-19. Annals of Internal Medicine, 2020:1-3spa
dc.relation.referencesMartin-Villares C, Molina-Ramirez C, Bartolome-Benito M, Bernal-Sprekelsen M. Outcome of 1890 tracheostomies for critical COVID-19 patients: a national cohort study in Spain. European Archives of Oto-Rhino-Laryngology, 2021; 278(5): 1605-1612spa
dc.relation.referencesHosey M, Needham D. Survivorship after COVID-19 ICU stay. Nature reviews Disease primers, 2020; 6(1): 1-2spa
dc.relation.referencesInoue S, Hatakeyama J, Kondo Y, Hifumi T, Sakuramoto H, Kawasaki T, Nishida O. Post‐intensive care syndrome: its pathophysiology, prevention, and future directions. Acute medicine & surgery, 2019; 6(3): 233-246spa
dc.relation.referencesHerridge M, Tansey C, Matté A, Tomlinson G, Diaz-Granados N, Cooper A, Cheung A. Functional disability 5 years after acute respiratory distress syndrome. New England Journal of Medicine, 2011; 364(14): 1293-1304spa
dc.relation.referencesHuppert L, Matthay M, Ware L. Pathogenesis of acute respiratory distress syndrome. In Seminars in respiratory and critical care medicine, 2019; 40(1): 31spa
dc.relation.referencesSchaller T, Hirschbühl K, Burkhardt K, Braun G, Trepel M, Märkl B, Claus R. Postmortem examination of patients with COVID-19. Jama, 2020; 323(24): 2518-2520spa
dc.relation.referencesDe Michele S, Sun Y, Yilmaz M, Katsyv I, Salvatore M, Dzierba A, Saqi A. Forty Postmortem Examinations in COVID-19 Patients: Two Distinct Pathologic Phenotypes and Correlation with Clinical and Radiologic Findings. American journal of clinical pathology, 2020; 154(6): 748-760spa
dc.relation.referencesMoodley Y, Scaffidi A, Misso N, Keerthisingam C, McAnulty R, Laurent G, Knight D. Fibroblasts isolated from normal lungs and those with idiopathic pulmonary fibrosis differ in interleukin-6/gp130-mediated cell signaling and proliferation. The American journal of pathology, 2003; 163(1): 345-354spa
dc.relation.referencesBharat A, Querrey M, Markov N, Kim S, Kurihara C, Garza-Castillon R, Budinger G. Lung transplantation for patients with severe COVID-19. Science translational medicine, 2020; 12(574): eabe4282spa
dc.relation.referencesLang M, Som A, Mendoza D, Flores E, Reid N, Carey D, Little B. Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT. The Lancet Infectious Diseases, 2020; 20(12): 1365-1366spa
dc.relation.referencesPatell R, Bogue T, Koshy A, Bindal P, Merrill M, Aird W, Zwicker J. Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood, The Journal of the American Society of Hematology, 2020; 136(11): 1342- 1346spa
dc.relation.referencesPavoni V, Gianesello L, Pazzi M, Stera C, Meconi T, Frigieri F. Evaluation of coagulation function by rotation thromboelastometry in critically ill patients with severe COVID-19 pneumonia. Journal of thrombosis and thrombolysis, 2020; 50(1): 281-286spa
dc.relation.referencesBikdeli, B., Madhavan, M. V., Gupta, A., Jimenez, D., Burton, J. R., Der Nigoghossian, C., ... & Group, T. C. (2020). Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research. Thrombosis and haemostasis, 202; 120(7): 1004-1024spa
dc.relation.referencesCarvalho-Schneider C, Laurent E, Lemaignen A, Beaufils E, BourbaoTournois C, Laribi S, Bernard L. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clinical Microbiology and Infection, 2021; 27(2): 258-263spa
dc.relation.referencesHuang C, Huang L, Wang Y, Li X, Ren L, Gu X, Cao B. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet, 2021; 397(10270): 220-232spa
dc.relation.referencesLindner D, Fitzek A, Bräuninger H, Aleshcheva G, Edler C, Meissner K, Westermann D. Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases. JAMA cardiology, 2020; 5(11): 1281- 1285spa
dc.relation.referencesSiripanthong, B., Nazarian, S., Muser, D., Deo, R., Santangeli, P., Khanji, M. Y., ... & Chahal, C. A. A. (2020). Recognizing COVID-19–related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. Heart rhythm, 17(9), 1463-1471spa
dc.relation.referencesWu Q, Zhou L, Sun X, Yan Z, Hu C, Wu J, Chen H. Altered lipid metabolism in recovered SARS patients twelve years after infection. Scientific reports, 2017; 7(1): 1-12spa
dc.relation.referencesLiu P, Blet A, Smyth D, Li H. The science underlying COVID-19: implications for the cardiovascular system. Circulation, 2020; 142(1): 68-78spa
dc.relation.referencesNordvig A, Fong K, Willey J, Thakur K, Boehme A, Vargas W, Elkind M. Potential neurologic manifestations of COVID-19. Neurology: Clinical Practice, 2021; 11(2): e135-e146spa
dc.relation.referencesBolay H, Gül A, Baykan B. COVID‐19 is a Real Headache! Headache: The Journal of Head and Face Pain, 2020; 60(7): 1415-1421spa
dc.relation.referencesPozo-Rosich, P. Headache & COVID-19: a short-term challenge with long-term insights. In Proc. AHSAM 2020 Virtual Annual Scientific Meeting (Infomedica, 2020); https://www.ahshighlights.com/ summariespodcasts/article/ headache-COVID-19-a-short- term-challenge-with- longterm-insightsspa
dc.relation.referencesKaseda E, Levine A. Post-traumatic stress disorder: A differential diagnostic consideration for COVID-19 survivors. The Clinical Neuropsychologist, 2020; 34(7-8): 1498-1514spa
dc.relation.referencesMazza M, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I. COVID19 BioB Outpatient Clinic Study group. Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain, behavior, and immunity, 2020; 89(1): 594-600spa
dc.relation.referencesSouth K, McCulloch L, McColl B, Elkind M, Allan S, Smith C. Preceding infection, and risk of stroke: an old concept revived by the COVID-19 pandemic. International Journal of Stroke, 2020; 15(7): 722-732spa
dc.relation.referencesReichard R, Kashani K, Boire N, Constantopoulos E, Guo Y, Lucchinetti C. Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology. Acta neuropathologica, 2020;140(1): 1-6spa
dc.relation.referencesAiello A, Farzaneh F, Candore G, Caruso C, Davinelli S, Gambino C, Accardi G. Immunosenescence and its hallmarks: how to oppose aging strategically? A review of potential options for therapeutic intervention. Frontiers in immunology, 2019; 10(1): 2247spa
dc.relation.referencesStevens J, King K, Robbins-Juarez S, Khairallah P, Toma K, Alvarado Verduzco H, Mohan S. High rate of renal recovery in survivors of COVID-19 associated acute renal failure requiring renal replacement therapy. PloS one, 2020; 15(12): e0244131spa
dc.relation.referencesWilbers T, Koning M. Renal replacement therapy in critically ill patients with COVID-19: A retrospective study investigating mortality, renal recovery, and filter lifetime. Journal of Critical Care, 2020; 60(1): 103-105spa
dc.relation.referencesJhaveri K, Meir L, Chang B, Parikh R, Wanchoo R, Barilla-LaBarca M, Hajizadeh N. Thrombotic microangiopathy in a patient with COVID-19. Kidney international, 2020; 98(2): 509-512spa
dc.relation.referencesSuwanwongse K, Shabarek N. Newly diagnosed diabetes mellitus, DKA, and COVID‐19: Causality or coincidence? A report of three cases. Journal of medical virology, 2021; 93(2): 1150-1153spa
dc.relation.referencesMateu-Salat M, Urgell E, Chico A. SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves’ disease after COVID19. Journal of Endocrinological Investigation, 2020; 43(10): 1527-1528spa
dc.relation.referencesSalvio G, Gianfelice C, Firmani F, Lunetti S, Balercia G, Giacchetti G. Bone Metabolism in SARS-CoV-2 Disease: Possible Osteoimmunology and Gender Implications. Clinical Reviews in Bone and Mineral Metabolism, 2020; 1-7spa
dc.relation.referencesArnold D, Hamilton F, Milne A, Morley A, Viner J, Attwood M, Barratt S. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax, 2021; 76(4): 399-401spa
dc.relation.referencesXu Y, Li X, Zhu B, Liang H, Fang C, Gong Y, Gong S. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nature medicine, 2020; 26(4): 502-505spa
dc.relation.referencesZeppa S, Agostini D, Piccoli G, Stocchi V, Sestili P. Gut Microbiota Status in COVID-19: An Unrecognized Player? Frontiers in cellular and infection microbiology; 2020, 10:1-10spa
dc.relation.referencesBradley K, Finsterbusch K, Schnepf D, Crotta S, Llorian M, Davidson S, Wack A. Microbiota-driven tonic interferon signals in lung stromal cells protect from influenza virus infection. Cell reports, 2019; 28(1): 245-256spa
dc.relation.referencesMiquel S, Martin R, Rossi O, Bermudez-Humaran L, Chatel J, Sokol H, Langella P. Faecalibacterium prausnitzii and human intestinal health. Current opinion in microbiology, 2013; 16(3): 255-261spa
dc.relation.referencesFreeman E, McMahon D, Lipoff J, Rosenbach M, Kovarik C, Desai S, Fox L. The spectrum of COVID-19–associated dermatologic manifestations: An international registry of 716 patients from 31 countries. Journal of the American Academy of Dermatology, 2020; 83(4): 1118-1129spa
dc.relation.referencesMirza F, Malik A, Omer S, Sethi A. Dermatologic manifestations of COVID‐19: a comprehensive systematic review. International journal of dermatology, 2021; 60(4): 418-450spa
dc.relation.referencesGenovese G, Moltrasio C, Berti E, Marzano A. Skin manifestations associated with COVID-19: current knowledge and future perspectives. Dermatology, 2020; 237(1): 1-12spa
dc.relation.referencesVilagut G, Valderas J, Ferrer M, Garin O, López-García E, Alonso J. Interpretación de los cuestionarios de salud SF-36 y SF-12 en España: componentes físico y mental. Medicina clínica, 2008; 130(19): 726-735spa
dc.relation.referencesGupta A, Madhavan M, Sehgal K, Nair N, Mahajan S, Sehrawat T, Landry D. Extrapulmonary manifestations of COVID-19. Nature medicine, 2020; 26(7): 1017-1032spa
dc.relation.referencesCarfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. Jama, 2020; 324(6): 603-605spa
dc.relation.referencesPettrone K, Burnett E, Link-Gelles R, Haight S, Schrodt C, England L, Killerby M. Characteristics and Risk Factors of Hospitalized and Nonhospitalized COVID-19 Patients, Atlanta, Georgia, USA, March–April 2020. Emerging infectious diseases, 2021; 27(4): 1164spa
dc.relation.referencesMcElvaney O, McEvoy N, McElvaney O, Carroll T, Murphy M, Dunlea D, McElvaney N. Characterization of the inflammatory response to severe COVID-19 illness. American journal of respiratory and critical care medicine, 2020; 202(6): 812-821spa
dc.relation.referencesSeeßle J, Waterboer T, Hippchen T, Simon J, Kirchner M, Lim A, Merle U. Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID-19): a prospective cohort study. Clinical infectious diseases, 2022; 74(7): 1191-1198spa
dc.relation.referencesLogue J, Franko N, McCulloch D, McDonald D, Magedson A, Wolf C, Chu H. Sequelae in adults at 6 months after COVID-19 infection. JAMA network open, 2021; 4(2): e210830-e210830spa
dc.relation.referencesTalman S, Boonman-de Winter L, De Mol M, Hoefman E, Van Etten R, De Backer I. Pulmonary function and health-related quality of life after COVID19 pneumonia. Respiratory Medicine, 2021; 176(1): 106272spa
dc.relation.referencesVaes A, Goërtz Y, Van Herck M, Machado F, Meys R, Delbressine J, Spruit M. Recovery from COVID-19: a sprint or marathon? 6-month follow-up data from online long COVID-19 support group members. ERJ open research, 2021; 7(2): 2345spa
dc.relation.referencesVlake J, Wesselius S, van Genderen M, van Bommel J, Boxma-de Klerk B, Wils E. Psychological distress and health-related quality of life in patients after hospitalization during the COVID-19 pandemic: A single-center, observational study. PloS one, 2021; 16(8): e0255774spa
dc.relation.referencesSudre C, Murray B, Varsavsky T, Graham M, Penfold R, Bowyer R, Steves C. Attributes and predictors of long COVID. Nature medicine, 2021; 27(4): 626-631spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.licenseAtribución-NoComercial-SinDerivadas 2.5 Colombia*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.subjectCOVID 19spa
dc.subjectManifestaciones posagudasspa
dc.subjectCalidad de vidaspa
dc.subjectFactores de riesgospa
dc.subject.lembInfecciones por coronavirusspa
dc.subject.lembCalidad de vidaspa
dc.subject.lembSignos y síntomasspa
dc.subject.subjectenglishCOVID 19spa
dc.subject.subjectenglishPost-acute manifestationsspa
dc.subject.subjectenglishQuality of lifespa
dc.subject.subjectenglishRisk factorsspa
dc.titleManifestaciones clínicas Posagudas y calidad de vida de pacientes atendidos por Covid-19 en una institución de la red pública de Barranquilla, de enero a julio del 2021spa
dc.type.driverinfo:eu-repo/semantics/bachelorThesisspa
dc.type.localTesis de Especializaciónspa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
CASTELLÓN DE LA ROSA.pdf
Tamaño:
1.32 MB
Formato:
Adobe Portable Document Format
Descripción:
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Especialización en Medicina Interna